An investor and analyst conference call will follow at 13:00 CET.
31 July 2025 – 1 mins read
“Our half year results reflect continued strong momentum, with growth across all three therapeutic areas, particularly in our rare liver disease franchise, which is expanding rapidly and progressing well,” said David Loew, Chief Executive Officer, Ipsen. “Building on that performance,…
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.
Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries, and our partnerships around the world, enable us to bring medicines to patients in more than 100 countries.
Discover Ipsen in 3 pages; our medicines and key figures, our objectives and our strategy.
If you are experiencing difficulties registering for the investor and analyst conference call, please contact: khalid.deojee@ipsen.com
Senior Manager, Investor Relations
H1 Results: a strong first half of 2025
Q1 2025 sales update
2024: A year of achievements and progress
Strong growth and expanding pipeline in the first half of 2024 drive raised guidance
Ipsen delivers FY 2023 results and anticipates four launches in 2024
2023 year to date and third-quarter sales results
A strong first half of 2023
Ipsen FY/Q4 2022 results–A word from CEO David Loew
A word from CEO David Loew
A message from CEO David Loew
